Bloom Burton reiterated their accumulate rating on shares of Knight Therapeutics (TSE:GUD) in a research note published on Friday.

Other equities research analysts have also recently issued reports about the stock. TD Securities boosted their price target on shares of Knight Therapeutics from C$9.50 to C$10.00 in a research report on Friday, August 10th. Raymond James set a C$10.25 price target on shares of Knight Therapeutics and gave the stock an outperform rating in a research report on Thursday, July 12th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The stock has an average rating of Buy and a consensus price target of C$10.15.

GUD traded up C$0.11 during trading on Friday, hitting C$8.30. The company had a trading volume of 198,100 shares, compared to its average volume of 134,380. Knight Therapeutics has a one year low of C$7.38 and a one year high of C$8.81.

Knight Therapeutics (TSE:GUD) last posted its quarterly earnings data on Thursday, November 8th. The company reported C$0.03 EPS for the quarter, meeting the consensus estimate of C$0.03. The company had revenue of C$3.22 million during the quarter, compared to the consensus estimate of C$2.26 million. As a group, equities analysts forecast that Knight Therapeutics will post 0.130000001435583 EPS for the current year.

Knight Therapeutics Company Profile

Knight Therapeutics Inc operates as a specialty pharmaceutical company in Canada and internationally. The company is involved in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its commercialized products include Movantik to treat opioid induced constipation; Impavido, an alkyllysophospholipid analogue drug for visceral and cutaneous Leishmaniasis; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Synergy family consumer health products; and Flat Tummy Tea, a herbal detox tea.

See Also: Bond

Analyst Recommendations for Knight Therapeutics (TSE:GUD)

Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with's FREE daily email newsletter.